| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:28525399:960 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:28525399:960?format=raw |
LEADER: 00960cam a2200289 a 4500
001 4027618
005 20221027021433.0
008 810826s1941 nju a 001 0 eng d
010 $a 41012270
035 $a(OCoLC)38253025
035 $a(OCoLC)ocm38253025
035 $9AJY5827HS
035 $a(NNC)4027618
035 $a4027618
040 $aNOH$cNOH$dOCP$dZCH
050 00 $aZ6665.S9$bM52 1941b
082 0 $a016.615222
110 2 $aMerck & Co.$0http://id.loc.gov/authorities/names/n81093623
245 10 $aSulfapyridine (2-sulfanilyl aminopyridine) :$bannotated bibliography.
260 $aRahway, N.J. :$bMerck & Co. Inc.,$c1941.
300 $a122 pages ;$c28 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
650 2 $aSulfanilamides.$0https://id.nlm.nih.gov/mesh/D013424
655 7 $aAbstracts.$2mesh$0https://id.nlm.nih.gov/mesh/D020504
650 0 $aSulfapyridine$vBibliography.
852 00 $boff,hsl$hRM671.S5$iM53 1941